Other
C group
C group is an intervention with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
1
33%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Recruiting1
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
recruiting133%
completed133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingnot_applicable
Rehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients.
NCT05720780
completedphase_4
Effect of Dexmedetomidine on Improving Intubating Conditions Without the Use of Muscle Relaxant
NCT06409377
unknownphase_2
Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
NCT01796717
Clinical Trials (3)
Showing 3 of 3 trials
NCT05720780Not Applicable
Rehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients.
NCT06409377Phase 4
Effect of Dexmedetomidine on Improving Intubating Conditions Without the Use of Muscle Relaxant
NCT01796717Phase 2
Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3